Associated Genetic Biomarkers
Insulin-like growth factor 1 receptor (IGF1R) is a gene that encodes a protein that is a receptor tyrosine kinase that binds insulin-like growth factor. Missense mutations, nonsense mutations, silent mutations, frameshift deletions, and in-frame deletions are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.
IGF1R is altered in 2.28% of all cancers with breast invasive ductal carcinoma, lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, and bladder urothelial carcinoma having the greatest prevalence of alterations .
The most common alterations in IGF1R are IGF1R Mutation (2.19%), IGF1R Amplification (0.44%), IGF1R Loss (0.05%), IGF1R R1246C (0.02%), and IGF1R G693S (0.02%) .
IGF1R status serves as an inclusion eligibility criteria in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials that contain IGF1R status as an inclusion criterion, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open).
The most frequent alterations to serve as inclusion eligibility criteria are IGF1R Expression and IGF1R Overexpression .
Significance of IGF1R in Diseases
Malignant Solid Tumor +
IGF1R is altered in 2.29% of malignant solid tumor patients .
IGF1R is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains IGF1R status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.